Leiden, The Netherlands, 31 January 2023 – VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces the appointment of Paul Roos as Chief Financial Officer (CFO). Paul has a wealth of experience in the international life sciences industry and investment banking, and will oversee VarmX’s finance department, whilst also bringing his leadership to the legal and IT functions.

Most recently, Paul served as CFO at Polyganics, a medical technology company that develops and commercializes bioresorbable devices for tissue repair and regeneration. He played a key role in the sale of Polyganics to Collagen Matrix in Q3 2022. Prior to Polyganics, he was CFO at IRX and Synthon, a privately-held specialty pharmaceutical company with gross revenue of over EUR 250 million and operations in six countries.

Paul began his career in the Corporate Finance division of Kempen & Co, a leading Dutch merchant bank. He advanced through a range of positions, ultimately becoming Executive Director of the Life Sciences/ Healthcare team. While at Kempen & Co, he advised on more than 35 M&A and capital market transactions, including successful exits and IPOs.

Paul holds Master’s degrees in Econometrics and Business Economics (both with honours) from the University of Amsterdam. In 2017, he completed the Emerging CFO program at Stanford University. Additionally, he was a non-executive director at Quirem Medical, a medical device company focused on selective internal radiotherapy, from 2015 until its acquisition by Terumo in 2020.

Paul will report directly to VarmX’s CEO, Dr. Jan Öhrström.

Dr. Jan Öhrström, CEO of VarmX, said: “We are delighted to have Paul on board as our new CFO at this crucial juncture in our company’s journey as our lead product, VMX-C001, is scheduled to enter pivotal trials at the end of this year. Having Paul’s wealth of experience and expertise in the life sciences and financial sectors will be a tremendous asset and we welcome him to the team.”

Paul Roos, CFO of VarmX, said: “I am excited to join VarmX. The company is at the cutting-edge of blood coagulation research and development and I believe its technology could have a major impact for patients taking FXa inhibitors. I have worked in the life sciences sector for many years and I am delighted to be joining such a talented team.”

About VarmX
VarmX is a pharmaceutical spin-off from the Leiden University Medical Center (LUMC), founded in 2016 by Professor Pieter Reitsma, a world leading expert in hemostasis and thrombosis. VarmX’s lead compound VMX-C001 is a modified recombinant blood factor X. The compound is being developed for the treatment of severe spontaneous bleeding in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The Company is supported by a strong syndicate of investors including Ysios Capital, INKEF Capital, Lundbeckfonden Ventures, EQT Life Sciences (formerly LSP), BioGeneration Ventures and the regional economic development fund, InnovationQuarter. For more information: www.varmx.com.